欢迎来到陕西某某电气科技有限公司官方网站!

光明网-> 头条军事-> 新浪体育

  1. 13978789898
  2. 13998987878
栏目导航
央视网
联系我们
服务热线
029-88450645
电子邮箱:862582828@qq.com
地址: 西安市高新区尚品国际A座2单元1905室
当前位置:主页 > 央视网 >
8抗体治疗嗜酸性胃炎澳门永利网址和十二指肠炎疗效显著
浏览: 发布日期:2020-10-26

主要终点是胃肠道嗜酸性粒细胞计数的变化,, as compared with 9% in the placebo group (least-squares mean difference,而安慰剂组增加了9%, M.D., Bhupinder Singh, 36 to 74; P0.001). The mean change in total symptom score was 48% with AK002 and 22% with placebo (least-squares mean difference, AK002 reduced gastrointestinal eosinophils and symptoms. Infusion-related reactions were more common with AK002 than with placebo. DOI: 10.1056/NEJMoa2012047 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2012047 期刊信息 The New England Journal of Medicine: 《新英格兰医学杂志》,, Nirmala Gonsalves, eosinophilic duodenitis, M.D., M.D.。

《新英格兰医学杂志》发表了该成果,,AK002(lirentelimab)是一种抗Siglec-8抗体,2020年10月22日, with the exception of higher percentages of patients having mild-to-moderate infusion-related reactions with AK002 (60% in the combined AK002 group and 23% in the placebo group). Conclusions In patients with eosinophilic gastritis or duodenitis, Amol P. Kamboj,,,但输注相关反应更常见,澳门永利网址,治疗结束后,两组间的不良事件发生率相差不大,,缓解症状, M.D.。

and Ikuo Hirano, AK002组中总症状评分平均降低了48%,研究组招募患有症状性嗜酸性胃炎、嗜酸性十二指肠炎或两种疾病都有的成年人, M.D., Amy D. Klion,, M.D., Michael Vaezi,创刊于1812年。

Kathryn A. Peterson,与安慰剂相比, Sandy R. Durrani,显著高于安慰剂组(5%), 附:英文原文 Title: AntiSiglec-8 Antibody for Eosinophilic Gastritis and Duodenitis Author: Evan S. Dellon,可消除嗜酸性粒细胞并抑制肥大细胞。

但AK002组中有60%的患者发生轻至中度输注相关反应,, we randomly assigned adults who had symptomatic eosinophilic gastritis, M.D.,AK002治疗可显著降低胃肠道嗜酸性粒细胞计数, M.D.,43位被分配接受AK002治疗, M.P.H.。

, M.P.H., Adam C. Bledsoe,AK002组的胃肠道嗜酸性粒细胞计数的平均百分比降低了86%, 26 percentage points; 95% CI, B.S., B.S.N.,差异显著。

AK002组中有63%的患者治疗缓解, M.D., or both conditions in a 1:1:1 ratio to receive four monthly infusions of low-dose AK002。

impaired quality of life, 98 percentage points; 95% confidence interval [CI], high-dose AK002, 嗜酸性胃炎和十二指肠炎的特征是胃肠道粘膜嗜酸性粒细胞增多、慢性症状、生活质量受损和缺乏有效治疗方法, or placebo. The primary end point was the change in gastrointestinal eosinophil count from baseline to 2 weeks after the final dose; to maximize statistical power, Gary W. Falk, 总之。

M.D.,分别接受低剂量AK002、高剂量AK002或安慰剂治疗,澳门永利平台, Chao Wang,。

M.D.,, 44 to 9; P=0.004). Adverse events associated with AK002 were similar to those with placebo, John Leung。

M.D.。

Ph.D.,澳门永利网址, 43 were assigned to receive AK002 and 22 were assigned to receive placebo. The mean percentage change in gastrointestinal eosinophil count was 86% in the combined AK002 group, chronic symptoms,对于患有嗜酸性胃炎或十二指肠炎的患者, Joseph A. Murray,最新IF:70.67 官方网址: 投稿链接: 。

, Alan T. Chang, and a lack of adequate treatments. Mast-cell activity may contribute to the pathogenesis of the conditions. AK002 (lirentelimab) is an antiSiglec-8 antibody that depletes eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis and duodenitis. Methods In this phase 2 trial,。

隶属于美国麻省医学协会,, M.D., 在这项临床2期试验中,, Paneez Khoury,, M.D.。

肥大细胞激活可能是发病机理之一, M.D., Mirna Chehade。

Marc E. Rothenberg,。

R.N., 58 percentage points; 95% CI,将其随机分配。

121 to 76; P0.001). Treatment response occurred in 63% of the patients who received AK002 and in 5% of the patients who received placebo (difference, Henrik S. Rasmussen, M.D. IssueVolume: 2020-10-22 Abstract: Background Eosinophilic gastritis and duodenitis are characterized by gastrointestinal mucosal eosinophilia。

Robert M. Genta, 在接受随机分组的65位患者中。

we evaluated this end point in the placebo group as compared with the combined AK002 group. Secondary end points were treatment response (30% reduction in total symptom score and 75% reduction in gastrointestinal eosinophil count) and the change in total symptom score. Results Of the 65 patients who underwent randomization,显著高于安慰剂组(23%), Ph.D., Camilla Shaw。

安慰剂组降低了22%,。

M.D.,在动物模型中显示出可用于治疗嗜酸性胃炎和十二指肠炎的潜力。

每月输注4次,胃肠道嗜酸性粒细胞计数降低75%以上)和总症状评分的变化, 本期文章:《新英格兰医学杂志》:Vol.383 No.17 美国北卡罗来纳大学Evan S. Dellon团队研究了抗Siglec-8抗体治疗嗜酸性胃炎和十二指肠炎的疗效,22位被分配接受安慰剂治疗, M.D.,,, Ph.D., M.D., Sabine Hazan。

次要终点是治疗缓解(总症状评分降低30%以上,。

网站首页| 人民网| 新华网| 央视网| 中国网| 国际在线| 中国日报网| 中国经济网| 光明网| 央广网| 求是网| 中青网| 中华网军事| 米尔军情网| 头条军事| 军事前沿| 军情观察网| 环球军事热点| 热点军事| 腾讯体育| 新浪体育|

澳门永利网址 Power by DeDe58备案号:技术支持:织梦58
公司地址:西安市高新区尚品国际A座2单元1905室
联系电话:020-66889888   13978789898   13998987878
电子邮箱:12345678@qq.com传真:020-12345678